<?xml version='1.0' encoding='utf-8'?>
<document id="9357398"><sentence text="Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction."><entity charOffset="0-10" id="DDI-PubMed.9357398.s1.e0" text="Olsalazine" /></sentence><sentence text="A patient with refractory Crohn's disease had two separate episodes of bone marrow suppression while receiving 50 to 75 mg 6-mercaptopurine a day and 1000 to 1750 mg olsalazine a day"><entity charOffset="123-139" id="DDI-PubMed.9357398.s2.e0" text="6-mercaptopurine" /><entity charOffset="166-176" id="DDI-PubMed.9357398.s2.e1" text="olsalazine" /><pair ddi="false" e1="DDI-PubMed.9357398.s2.e0" e2="DDI-PubMed.9357398.s2.e0" /><pair ddi="false" e1="DDI-PubMed.9357398.s2.e0" e2="DDI-PubMed.9357398.s2.e1" /></sentence><sentence text=" This adverse reaction necessitated dose reduction of 6-mercaptopurine on the first occasion and withdrawal of 6-mercaptopurine and olsalazine on the second occasion"><entity charOffset="54-70" id="DDI-PubMed.9357398.s3.e0" text="6-mercaptopurine" /><entity charOffset="111-127" id="DDI-PubMed.9357398.s3.e1" text="6-mercaptopurine" /><entity charOffset="132-142" id="DDI-PubMed.9357398.s3.e2" text="olsalazine" /><pair ddi="false" e1="DDI-PubMed.9357398.s3.e0" e2="DDI-PubMed.9357398.s3.e0" /><pair ddi="false" e1="DDI-PubMed.9357398.s3.e0" e2="DDI-PubMed.9357398.s3.e1" /><pair ddi="false" e1="DDI-PubMed.9357398.s3.e0" e2="DDI-PubMed.9357398.s3.e2" /><pair ddi="false" e1="DDI-PubMed.9357398.s3.e1" e2="DDI-PubMed.9357398.s3.e1" /><pair ddi="false" e1="DDI-PubMed.9357398.s3.e1" e2="DDI-PubMed.9357398.s3.e2" /></sentence><sentence text=" The patient's red blood cell thiopurine methyltransferase (TPMT) activity was 1"><entity charOffset="30-40" id="DDI-PubMed.9357398.s4.e0" text="thiopurine" /></sentence><sentence text="2 U per milliliter red blood cells (low normal range) and her TPMT genotype was wild-type sequence for all known alleles of TPMT that result in low TPMT enzyme activity" /><sentence text=" In vitro enzyme kinetic studies confirmed the hypothesis that olsalazine and olsalazine-O-sulfate are potent noncompetitive inhibitors of recombinant human TPMT"><entity charOffset="63-73" id="DDI-PubMed.9357398.s6.e0" text="olsalazine" /><entity charOffset="78-98" id="DDI-PubMed.9357398.s6.e1" text="olsalazine-O-sulfate" /><pair ddi="false" e1="DDI-PubMed.9357398.s6.e0" e2="DDI-PubMed.9357398.s6.e0" /><pair ddi="false" e1="DDI-PubMed.9357398.s6.e0" e2="DDI-PubMed.9357398.s6.e1" /></sentence><sentence text=" We suggest that the patient's relatively low baseline level of TPMT activity was inhibited by olsalazine and olsalazine-O-sulfate, leading to decreased clearance of 6-mercaptopurine and its accumulation"><entity charOffset="95-105" id="DDI-PubMed.9357398.s7.e0" text="olsalazine" /><entity charOffset="110-130" id="DDI-PubMed.9357398.s7.e1" text="olsalazine-O-sulfate" /><entity charOffset="166-182" id="DDI-PubMed.9357398.s7.e2" text="6-mercaptopurine" /><pair ddi="false" e1="DDI-PubMed.9357398.s7.e0" e2="DDI-PubMed.9357398.s7.e0" /><pair ddi="false" e1="DDI-PubMed.9357398.s7.e0" e2="DDI-PubMed.9357398.s7.e1" /><pair ddi="false" e1="DDI-PubMed.9357398.s7.e0" e2="DDI-PubMed.9357398.s7.e2" /><pair ddi="false" e1="DDI-PubMed.9357398.s7.e1" e2="DDI-PubMed.9357398.s7.e1" /><pair ddi="false" e1="DDI-PubMed.9357398.s7.e1" e2="DDI-PubMed.9357398.s7.e2" /></sentence><sentence text=" This ultimately increased intracellular 6-thiopurine nucleotide levels to toxic concentrations, which caused bone marrow suppression"><entity charOffset="41-64" id="DDI-PubMed.9357398.s8.e0" text="6-thiopurine nucleotide" /></sentence><sentence text="" /></document>